Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.43)
# 3,834
Out of 4,681 analysts
14
Total ratings
36.36%
Success rate
-47.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Initiates: Buy | $38 | $2.40 | +1,483.33% | 1 | Nov 20, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $2.81 | +184.70% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $23.46 | +326.26% | 2 | May 30, 2024 | |
| HEPA Hepion Pharmaceuticals | Downgrades: Hold | n/a | $0.63 | - | 1 | Dec 7, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $2.03 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $1.07 | +13,918.69% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $5.30 | +183.02% | 1 | Jun 29, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $22.01 | +308.91% | 1 | Dec 9, 2022 | |
| VERU Veru Inc. | Maintains: Buy | $29 → $31 | $0.69 | +4,361.72% | 2 | May 18, 2022 | |
| DRMA Dermata Therapeutics | Initiates: Buy | $3,360 | $1.27 | +264,466.93% | 1 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $0.53 | +60,667.19% | 1 | Mar 30, 2021 |
Palisade Bio
Nov 20, 2024
Initiates: Buy
Price Target: $38
Current: $2.40
Upside: +1,483.33%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $2.81
Upside: +184.70%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $23.46
Upside: +326.26%
Hepion Pharmaceuticals
Dec 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.63
Upside: -
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.03
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $1.07
Upside: +13,918.69%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $5.30
Upside: +183.02%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $22.01
Upside: +308.91%
Veru Inc.
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.69
Upside: +4,361.72%
Dermata Therapeutics
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $1.27
Upside: +264,466.93%
Mar 30, 2021
Initiates: Buy
Price Target: $320
Current: $0.53
Upside: +60,667.19%